Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLTogether1 for newly diagnosed acute lymphoblastic leukemia in children and young adults
NL-OMON55098Phase 3Recruiting
- Sponsor
- Karolinska University Hospital
- Start
- Jul 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of doxorubicin, vincristine, dexamethasone, inotuzumab ozogamicin, tioguanine and 2 more in acute lymphoblastic leukemia (ALL), B cell acute lymphoblastic leukemia (B-ALL) and Precursor T-cell lymphoblastic leukemia/lymphoma (T-LBL/ALL) (10 arms), sponsored by Karolinska University Hospital. Primary endpoints: Event-free survival, Disease-free survival and 1 more. Started Jul 2020; status: recruiting.
02
Drugs
doxorubicinvincristinedexamethasoneinotuzumab ozogamicintioguanine
03
Conditions
acute lymphoblastic leukemia (ALL)B cell acute lymphoblastic leukemia (B-ALL)Precursor T-cell lymphoblastic leukemia/lymphoma (T-LBL/ALL)
Beyond the preview
Go deeper on NL-OMON55098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55098.